Update on trials of Celator Pharma's cancer candidate; Can turmeric treat Alzheimer's?;

> Celator Pharmaceuticals' stock rose on positive clinical trial results of its Phase II candidate for acute myeloid leukemia, which uses its CombiPlex delivery platform. Release

> Vanderbilt University is studying curcumin, found in the spice turmeric, as a treatment for Alzheimer's disease. "Curcumin has demonstrated ability to enter the brain, bind and destroy the beta-amyloid plaques present in Alzheimer's with reduced toxicity," said biomedical engineering professor Wellington Pham. Story

> University of Florida spinoff Prometheon Pharma is promoting its needle-free transdermal patch to external partners. The patch contains a formulation that melts into a gel upon contact with the skin, and can deliver drugs at a constant and consistent rate, according to the company. Release

> BioLight Life Sciences announced that it has invested in a new ophthalmic company which has the rights to novel drug delivery platform developed by Hebrew University in Israel. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.